Sign in Subscribe

immunotherapy

A collection of 61 issues

Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

Skip to content The CRC Digest ◆ TRIAL DATA Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from

KRAS mutations drive immune evasion through RNA modifications

Skip to content The CRC Digest ◇ RESEARCH KRAS mutations drive immune evasion through RNA modifications Preclinical research found that KRAS mutations remodel RNA m6A modifications to increase CD73 expression, promoting immune evasion in colorectal cancer. (Cancer Research) This content is informational only and does not constitute medical advice. Always consult

Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to

Immunotherapy May Reshape Fertility Counseling for Young Women with CRC

Skip to content The CRC Digest Immunotherapy May Reshape Fertility Counseling for Young Women with CRC A narrative review found that immune checkpoint inhibitors for dMMR/MSI-H colorectal cancer may affect reproductive-age women through direct reproductive uncertainty (including endocrine toxicities and hypothesized, but currently unproven, direct gonadal effects) and potential

PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH PLOD2 Protein Linked to Tumor Growth in Colorectal Cancer Preclinical research using single-cell RNA sequencing found that PLOD2, often overexpressed in colorectal cancer, has been implicated in promoting tumor growth and epithelial-mesenchymal transition. Functional assays in CRC cell lines with PLOD2 knockdown showed

Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Real-World Study Examines Immune-Related Side Effects in Neoadjuvant Immunotherapy A multicenter study of 452 colorectal cancer patients who received neoadjuvant immunotherapy analyzed the incidence of immune-related adverse events and perioperative outcomes following curative surgery. (Zhonghua Wei Chang Wai Ke Za Zhi)

KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy

Skip to content The CRC Digest ◇ RESEARCH KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring

Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical

Endocrine side effects vary by immunotherapy regimen in CRC

Skip to content The CRC Digest Endocrine side effects vary by immunotherapy regimen in CRC A network meta-analysis of six randomized trials found that pembrolizumab and ICI plus tyrosine kinase inhibitor combinations significantly increased hypothyroidism risk, while hyperthyroidism was higher with ICI-TKI and ICI-chemotherapy-antiangiogenic regimens. (Frontiers in Immunology) This content

Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapy An international study of 1,175 patients from 34 centers examined how grade 3 or higher immune-related adverse events correlate with progression-free survival and overall survival in